Sun Pharma share price: Q4 FY26 update and targets

What moved Sun Pharma stock

Sun Pharmaceutical Industries Ltd. traded lower in the latest sessions even after reporting strong fourth-quarter earnings for FY26 and announcing a final dividend for shareholders. The price action suggested investors were cautious in the near term despite healthy growth commentary around profit and revenue. In the market, the stock saw both mild declines and sharper drops across different trading sessions mentioned in the data, reflecting how quickly sentiment can swing on large-cap pharma names. Brokerages, however, largely stayed constructive, with multiple firms reiterating Buy ratings and target prices well above prevailing market quotes.

The trading updates show Sun Pharma changing hands around the mid-₹1,800 levels after results, with day-to-day moves driven by a mix of earnings digestion, technical levels, and separate concerns around a potential large overseas acquisition. Another overhang highlighted was policy risk in the US market, including possible tariff changes later in 2026.

Sun Pharma share price today on NSE: intraday levels

On the NSE, Sun Pharma shares were trading at ₹1,838.60 around 12:16 pm on May 25, down ₹6 or 0.33% for the day. The stock opened at ₹1,840 and moved in a wide band, touching an intraday high of ₹1,849 and a low of ₹1,825 during the session.

Separately, another snapshot shows the stock at ₹1,835.60, down 0.49% from a previous close of ₹1,844.60 (last updated 25 May, 2026, 04:24 AM IST). These moves indicate a cautious tone rather than a disorderly sell-off, with the stock oscillating around immediate supports.

Post-results dip: what happened on May 22 close

Sun Pharma shares also saw sharper pressure immediately after the Q4FY26 earnings announcement. On Friday, May 22, 2026, the stock declined 2.43% to close at ₹1,845.20 on the BSE. On the NSE, it closed at ₹1,844.60, down 2.47%.

Another data point states the share price was ₹1,844.60 as on 22 May, 2026, 03:59 PM IST, and was down 2.47% versus a previous share price of ₹1,891.3. The immediate reaction suggests part of the market used the results event as a profit-booking trigger after a strong run-up.

Q4FY26 earnings: the key number disclosed

The data provided includes one explicit quarterly financial metric: Sun Pharma posted a net profit of ₹2,714.03 crore in its last quarter. The narrative in the source also describes the quarter as “strong”, with “healthy growth in profit and revenue”, but without giving additional numbers for revenue, margins, or segment performance.

Given the limited disclosed figures in the provided text, the market reaction appears to have been less about whether earnings were good and more about how much was already priced in, and what near-term risks investors were focusing on.

Final dividend announcement: headline support, limited detail

Sun Pharma announced a final dividend alongside its Q4FY26 results, which typically provides a near-term sentiment anchor for large institutional investors. The provided text does not specify the dividend amount or record date.

Even so, the stock still traded lower in subsequent sessions, indicating that dividend news did not offset concerns around valuation, technical levels, or separate event risks highlighted elsewhere in the text.

Brokerage view: Motilal Oswal stays positive

Motilal Oswal Financial Services maintained a “Buy” recommendation on Sun Pharma with a target price of ₹2,120, indicating a potential upside of around 15% from the then-current levels cited. The brokerage also said it was building in 12% earnings CAGR over FY26-28 and reiterated its Buy stance.

This is important because it frames how at least one major domestic brokerage is looking beyond the immediate post-results volatility and focusing on multi-year earnings compounding.

HDFC Securities raises target to ₹2,120

HDFC Securities also retained a ‘Buy’ rating after the Q4 results and upgraded its target price to ₹2,120 per share, from an earlier target of ₹2,000. This aligns with Motilal Oswal’s target level and signals that, despite the post-results dip, at least some analysts saw enough fundamental strength to justify higher fair value estimates.

Another brokerage reference in the data indicates a ‘Buy’ rating with a target price of ₹2,000, and Nomura is also stated to have a ‘Buy’ rating on the stock.

Analyst ratings: where consensus stands

The rating distribution in the provided text shows broad optimism:

• 12 analysts have a strong buy rating
• 16 analysts have a buy rating
• 2 analysts have a sell rating

This mix suggests a positive consensus, though not unanimous, which is typical for large-cap names where near-term catalysts can cut both ways.

52-week range and recent returns

Sun Pharma’s 52-week high is ₹1,917.15 and 52-week low is ₹1,547.25. The stock also hit its 52-week high of ₹1,917.15 earlier in the same week on Tuesday, May 19, 2026. After the subsequent decline, the text notes the counter was still trading less than 4% below its record peak.

Performance snapshots in the text add context:

• Up 7.26% in the current year
• Down 1.79% over the last 5 days

Acquisition buzz: Organon deal size becomes a market worry

A separate strand of the provided content links a sharper sell-off to reported developments around a potential acquisition. The text says Sun Pharma was “down today” on news of a large acquisition bid, and market participants were cautious about a $12 billion deal size, citing concerns around debt, integration, and execution risk.

Another segment states the company was reportedly moving toward the final stage of a proposed $12-billion acquisition of Organon & Co, which, if completed, could be the largest overseas M&A by an Indian pharma company. The same segment notes investors booked profits amid these reports.

US tariff risk: policy uncertainty enters the narrative

The text also flags US policy concerns, stating that the US plans to impose up to 100% tariffs on patented drug imports from late 2026. It adds that some drugs, including Ilumya, could face around 15% tariffs, which could pressure profitability or require price actions that may affect market share.

These points are presented as risk factors that can dominate headlines even when quarterly earnings are strong.

Technical levels mentioned by analysts

Technical commentary in the source text describes a “bearish” undertone after the stock broke ₹1,700 support on the daily chart (in the context of a separate 5% fall episode). The levels cited include:

• Immediate support near ₹1,600
• Resistance around ₹1,700
• A breakdown below ₹1,600 could drag the stock towards ₹1,530

These levels are relevant for traders watching support-resistance, but they sit alongside brokerage targets that reflect longer-term valuation views.

Key figures at a glance

Broker targets and ratings snapshot

Market impact: what investors are weighing

The market reaction described in the text shows two forces operating together. On one side, Sun Pharma delivered a strong quarter and announced a final dividend, supporting longer-term confidence and helping brokerages stay positive. On the other, near-term price action remained sensitive to event risks such as a potential $12-billion acquisition and US tariff uncertainty.

For investors, this combination often leads to range-bound trading: strong fundamentals can provide a floor, but headline-driven concerns can cap near-term upside until there is clarity on deal structure, funding, and regulatory policy direction.

Why the story matters

Sun Pharma is one of India’s most widely held pharmaceutical stocks, so post-results price movement can influence sector sentiment more broadly. The data also shows investors paying close attention to peak levels near the 52-week high, making the stock vulnerable to profit-taking after sharp rallies.

At the same time, the presence of multiple Buy ratings and targets clustered at ₹2,000 to ₹2,120 suggests that the Street’s base case remains constructive, even if the market is currently pricing in additional risk for large M&A and policy changes.

Conclusion

Sun Pharma shares traded lower after Q4FY26 results and a final dividend announcement, with investors staying cautious amid valuation digestion and separate concerns around a potential $12-billion Organon acquisition and US tariff risks. Brokerages cited in the text largely maintained Buy ratings, with target prices extending up to ₹2,120. The next set of market-moving cues, based on the provided information, will be any further clarity on the acquisition reports and how US tariff policy evolves toward late 2026.